Anders Dige

Anders Dige

Auto-generated profile, based on publicly available information

Anders Dige

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, 8200 Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Gastroenterology
Verified
Journal Article
Open access
PDF file
ADAnders Dige
Anders Dige
HHHelene Tarri Hougaard
Helene Tarri Hougaard
JAJørgen Agnholt
Jørgen Agnholt
BPBodil Ginnerup Pedersen
Bodil Ginnerup Pedersen
MTMichaela Tencerová
Michaela Tencerová
LLLilli Lundby
Lilli Lundby
Perianal fistulas are common in patients with Crohn´s disease (CD). Injections of cultured autologous and allogeneic adipose tissue-derived stem cells have been shown to heal CD-associated fistulas. Unfortunately, this treatment is time-consuming and expensive. We investigated the effects of injecting freshly collected autologous adipose tissue into perianal fistulas in patients with CD. In a prospective interventional study freshly collected autologous adipose tissues were injected into complex perianal fistulas of 21 patients with CD, from March 2015 through June 2018. The primary endpoint was complete fistula healing (no symptoms of discharge, no visible external fistula opening in the perineum, and no internal opening detected by rectal digital examination) 6 months after the last injection. We performed pelvic magnetic resonance imaging (MRI) to confirm fistula resolution in patients with inter-sphincter and trans-sphincter fistulas who demonstrated complete healing at clinical examination. Patients without complete fistula healing after 6 weeks and those with later relapse were offered additional injections. No controls were included. Six months after the last adipose tissue injection, 12 patients (57%) had complete fistula healing. Three patients (14%) had ceased fistula secretion and 1 patient (5%) reported reduced secretion. Among 10 patients with trans-sphincter or inter-sphincter fistulas, MRI revealed complete fistula resolution in 9 patients and a markedly reduced gracile fistula in the remaining patient. Of the 12 patients with complete fistula healing, 9 (43% of total) required 1 injection, 2 patients (10% of total) required 2 injections, and 1 patient (5% of total) required 3 injections. The predominant adverse effect of was post-procedure proctalgia lasting a few days. Two patients developed small abscesses, 1 had urinary retention, and 1 had minor bleeding during liposuction. In a study of 21 patients with CD and perianal fistulas, we found injection of recently collected autologous adipose tissue to be safe and result in complete fistula healing in 57% of the patients. ClinicalTrials.gov no: NCT03803917

1 April 2013 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
ADAnders Dige
Anders Dige
SSSidsel Støy
Sidsel Støy
TRTue K. Rasmussen
Tue K. Rasmussen
JKJens Kelsen
Jens Kelsen
CHChristian L. Hvas
Christian L. Hvas
JAJørgen Agnholt
Jørgen Agnholt
Th17 cells, a subset of CD4+ T cells that produce interleukin (IL)-17A, IL-17F, IL-21, IL-22, IL-26, and the chemokine CCL20 are critically involved in the mucosal inflammation observed in Crohn's disease (CD). However, their role as mediators of inflammation in CD has been questioned by a recent clinical trial in which anti-IL-17A (secukinumab) treatment was ineffective. Besides being pro-inflammatory, Th17-related cytokines mediate mucosal protective functions. We aimed to investigate the role of Th17 cells in CD inflammation. Blood samples from 26 patients with active CD and 10 healthy controls (HC) were analyzed for levels of IL-17A-, IL-21- and IL-22-producing CD45RO+CD4+ T cells using multicolor flow cytometry. Samples were analyzed before and during adalimumab treatment to compare intra-individual changes during active and quiescent disease. CD patients had statistically significantly higher levels of IL-17-A-, IL-21- and IL-22-producing CD45RO+CD4+ T cells in both active and quiescent disease compared with HC. Baseline levels of IL-21 and IL-22 producing CD45RO+CD4+ T cells correlated inversely with mucosal inflammation estimated by fecal calprotectin. Patients who responded to adalimumab treatment demonstrated a 2- to 3-fold increase in levels of IL-17A- and IL-21-producing CD45RO+CD4+ T cells in quiescent disease compared with active disease. Our data support the involvement of Th17 cells and IL-21- and IL-22-producing CD45RO+CD4+ T cells in CD. Because patients had higher levels in quiescent disease compared with active CD, we question whether Th17 cells are promoters of inflammation. Instead, Th17 cells may counterbalance inflammation and maintain gut homeostasis.

26 November 2014 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ADAnders Dige
Anders Dige
SSSidsel Støy
Sidsel Støy
KTKaren Louise Thomsen
Karen Louise Thomsen
CHChristian Lodberg Hvas
Christian Lodberg Hvas
JAJørgen Agnholt
Jørgen Agnholt
Henning GrønbækHenning Grønbæk
Henning Grønbæk

14 December 2016 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
ADAnders Dige
Anders Dige
TRTue Kruse Rasmussen
Tue Kruse Rasmussen
PNPeter Nejsum
Peter Nejsum
RHRikke Hagemann‐Madsen
Rikke Hagemann‐Madsen
Andrew WilliamsAndrew Williams
Andrew Williams
CHChristian L Hvas
Christian L Hvas

5 January 2016 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
ADAnders Dige
Anders Dige
MMMaria Magnusson
Maria Magnusson
LÖLena Öhman
Lena Öhman
CHChristian Lodberg Hvas
Christian Lodberg Hvas
JKJens Kelsen
Jens Kelsen
JAJørgen Agnholt
Jørgen Agnholt
Objective Anti-TNF-α treatment constitutes a mainstay in the treatment of Crohn’s disease (CD), but its mechanisms of action are not fully understood. We aimed to investigate the effects of adalimumab, a human monoclonal TNF-α antibody, on macrophage (MQ) and dendritic cell (DC) subsets in mucosal biopsies and peripheral blood. Material and methods Intestinal biopsies and blood samples were obtained from 12 different CD patients both before and 4 weeks after the initiation of the induction of adalimumab treatment. Endoscopic disease activity was estimated by the Simple Endoscopic Score for Crohn’s Disease. Biopsies were obtained from inflamed and non-inflamed areas. The numbers of lamina propria CD14 + DRint and CD14 + DRhi MQs, CD141+, CD141− and CD103+ DCs subsets, and circulating monocytes and DCs were analyzed using flow cytometry. Results At baseline, we observed higher numbers of DRint MQs and lower numbers of CD103+ DCs in inflamed versus non-inflamed mucosa [843 vs. 391/105 lamina propria mononuclear cells (LPMCs) (p < 0.05) and 9 vs. 19 × 105 LPMCs (p = 0.01), respectively]. After four weeks of adalimumab treatment, the numbers of DRint MQs decreased [843 to 379/105 LPMCs (p = 0.03)], whereas the numbers of CD103+ DCs increased [9–20 × 105 LPMCs (p = 0.003)] compared with baseline. In peripheral blood, no alterations were observed in monocyte or DC numbers between baseline and week 4. Conclusions In CD, mucosal inflammation is associated with high numbers of DRint MQs and low numbers of CD103+ DCs. This composition of intestinal myeloid subsets is reversed by anti-TNF-α treatment. These results suggest that DRint MQs play a pivotal role in CD inflammation.

26 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MBMia Bendix
Mia Bendix
ADAnders Dige
Anders Dige
SJSøren Peter Jørgensen
Søren Peter Jørgensen
JDJens Frederik Dahlerup
Jens Frederik Dahlerup
BBBo Martin Bibby
Bo Martin Bibby
JAJørgen Agnholt
Jørgen Agnholt
Background: Seven weeks of high-dose vitamin D treatment decreases intestinal IL17A and IFN-γ mRNA expression in active Crohn’s disease (CD). In this follow-up study, we investigated whether seven-week vitamin D treatment affected the infliximab response in the following 45 weeks compared to placebo. Methods: CD patients (n = 40) were initially randomised into four groups: infliximab + vitamin-D; infliximab + placebo-vitamin-D; placebo-infliximab + vitamin-D; and placebo-infliximab + placebo-vitamin-D. Infliximab (5 mg/kg) or placebo-infliximab was administered at weeks 0, 2 and 6. Vitamin D (5 mg bolus followed by 0.5 mg/day for 7 weeks) or placebo-vitamin D was handed out. After the 7-week vitamin D period, all patients received infliximab during follow-up. Results are reported for Group D+ (infliximab + vitamin-D and placebo-infliximab + vitamin-D) and Group D- (infliximab + placebo-vitamin-D and placebo-infliximab + placebo-vitamin-D). Results: Group D- patients had greater needs for infliximab dose escalation during follow-up compared to group D+ (p = 0.05). Group D+ had lower median calprotectin levels week 15 (p = 0.02) and week 23 (p = 0.04) compared to group D-. Throughout follow-up, group D+ had 2.2 times (95% CI: 1.1–4.3) (p = 0.02) lower median CRP levels compared with group D-. Conclusions: Seven weeks high-dose vitamin D treatment reduces the need for later infliximab dose-escalation and reduces inflammatory markers. EudraCT no. 2013-000971-34.